

## DIRECTORS AND SENIOR MANAGEMENT

### BOARD OF DIRECTORS

Our Board comprises of eight Directors, including two executive Directors, three non-executive Directors and three independent non-executive Directors. The powers and duties of our Board include determining our business and investment plans, preparing our annual financial budgets and final reports, and exercising other powers, functions and duties as conferred by the Articles. We [have entered] into a service agreement with each of our executive Directors and a letter of appointment with each of our non-executive Directors and independent non-executive Directors.

The table below sets out certain information in respect of our Directors:

<u>Name</u>	<u>Age</u>	<u>Date of joining our Group</u>	<u>Date of appointment as Director</u>	<u>Existing position(s) in our Group</u>	<u>Roles and responsibilities</u>	<u>Relationship with other Directors or senior management</u>
Mr. Peng Bo (彭博)	53	May 16, 2012	September 30, 2020	Non-executive Director and chairman of our Board	Responsible for overseeing management and operations of our Group	None
Mr. Xie Zhiyong (謝志永)	45	April 1, 2012	November 2, 2020	Executive Director and president	Responsible for the overall management of our Group	None
Mr. Wang Yiqun Bruce (王亦群)	57	June 15, 2015	November 2, 2020	Executive Director and executive vice president	Responsible for the R&D and international business of our Group	None
Mr. Wang Lin (王琳)	48	September 23, 2021	September 23, 2021	Non-executive Director	Responsible for overseeing management and operations of our Group	None
Ms. Wu Xia (吳夏)	40	November 19, 2021	November 19, 2021	Non-executive Director	Responsible for overseeing management and operations of our Group	None
Dr. Xu Yi (胥義)	46	[●]	[●]	Independent non-executive Director	Providing independent advice to the Board	None
Dr. Zhang Haixiao (張海曉)	50	[●]	[●]	Independent non-executive Director	Providing independent advice to the Board	None
Mr. Siu Chi Hung (蕭志雄)	51	[●]	[●]	Independent non-executive Director	Providing independent advice to the Board	None

---

## DIRECTORS AND SENIOR MANAGEMENT

---

### Chairman of the Board

**Mr. Peng Bo (彭博)**, aged 53, was appointed as our Director on September 30, 2020 and re-designated as our non-executive Director and chairman of our Board on December 16, 2021. Mr. Peng joined our Group in May 2012 and has been serving as the chairman of the board of directors of MP NeuroTech Shanghai since then. He is primarily responsible for overseeing the management and operations of our Group.

Mr. Peng has over 20 years of experience in medical device industry. Mr. Peng joined the MicroPort Group in July 2001 and since then, has successively served various positions in MicroPort Group, including marketing development manager, director of human resources, vice president of domestic marketing and sales and chief marketing officer. Mr. Peng has been serving as the chief marketing officer of Shanghai MicroPort in 2008 and the chairman of the Greater China Executive Committee of MicroPort since 2013, where he is primarily responsible for the overall sales and marketing management. Since May 2012, Mr. Peng has also been serving as the chairman of Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (上海微創心脈醫療科技(集團)股份有限公司) (“**MicroPort Endovascular**”), a company principally engaged in endovascular and peripheral vascular devices whose shares are listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange (stock code: 688016).

Mr. Peng obtained his bachelor’s degree in computer science from Changchun Institute of Optics and Fine Mechanics (長春光學精密機械學院) (now known as Changchun University of Science and Technology (長春理工大學)) in the PRC in July 1990 and his master’s degree in business administration from Shanghai University of Finance and Economics (上海財經大學) in November 2004.

### Executive Directors

**Mr. Xie Zhiyong (謝志永)**, aged 45, was appointed as our Director on November 2, 2020 and re-designated as our executive Director on December 16, 2021. He joined our Group in April 2012 and has been serving as our president since then and is mainly responsible for the overall management of our Group. Mr. Xie also holds various directorships and management positions in our Group companies including a director and general manager of MP NeuroTech Shanghai since May 2012.

Mr. Xie had over 22 years of experience in the neuro-intervention industry. Prior to joining our Group, from January 1999 to March 2012, Mr. Xie successively served as a R&D engineer, a manager of the stent R&D department and a R&D director at Shanghai MicroPort Medical, where he was primarily responsible for R&D of coronary stents, peripheral vascular products and neuro-interventional products including leading the R&D work for *APOLLO*. Mr. Xie was awarded the Second Prize for National Science and Technology Award (國家科學技術進步獎二等獎) by the State Council in February 2007 and December 2014, the First Prize for the Science and Technology Award of Shanghai (上海市科學技術獎一等獎) by the Shanghai Municipal Government in November 2009 and the Second Prize for the Science and Technology Award of Shanghai Pudong New Area (上海市浦東新區科技進步獎二等獎) by the People’s Government of Shanghai Pudong New Area in January 2017. He was also recognized as a Leading Talent of Shanghai (上海市領軍人才) by the Organization Department of CPC Shanghai Committee (中共上海市委組織部) and Shanghai Municipal Human Resources and Social Security Bureau (上海市人力資源和社會保障局) in February 2020 and a Senior Engineer (正高級工程師) by the Shanghai Municipal Human Resources and Social Security Bureau (上海市人力資源和社會保障局) in December 2020.

---

## DIRECTORS AND SENIOR MANAGEMENT

---

Mr. Xie graduated from Shanghai Jiao Tong University (上海交通大學) in the PRC with a major in communications engineering in July 2004 and obtained his master’s degree in project management from Zhejiang University (浙江大學) in the PRC in June 2011.

**Mr. Wang Yiqun Bruce (王亦群)**, aged 57, was appointed as our Director on November 2, 2020 and re-designated as our executive Director on December 16, 2021. He joined our Group in June 2015 and has been serving as our executive vice president since then. Mr. Wang is mainly responsible for the R&D and the international business of our Group. He also holds various directorships and management positions in our Group companies including a director of MP NeuroTech Shanghai since December 2015.

Mr. Wang has over 25 years of experience in the neuro-intervention industry. Prior to joining our Group, from September 1986 to December 1990, Mr. Wang worked as an assistant engineer at 621 Research Institute of Aviation Industry Corporation (航空工業總公司621研究所), a comprehensive scientific research institute principally engaged in the technological and engineering research of advanced aeronautical materials. From 1991 to 1995, Mr. Wang served as a researcher at the University of Florida in the United States where he was primarily conducting the research of materials science. From November 1995 to 2013, Mr. Wang successively served as a principal engineer, senior marketing manager and group product manager at Boston Scientific Corporation, a manufacturer of medical devices used in interventional medical specialties, where he was primarily responsible for the R&D and the sales and marketing of neuro-interventional products. From 2013 to 2015, Mr. Wang served as a managing director and chief executive officer of Medinova Global LLC, a company principally engaged in the development and consultancy of marketing channels for medical device companies. Mr. Wang was recognized as an expert of the Shanghai Foreign Elite Talent Introduction Program (上海海外高層次人才引進計畫) in 2016. He was awarded the First Prize for Science and Technology Award of Shanghai (上海市科技進步獎一等獎) by the Shanghai Municipal People’s Government (上海市人民政府) in 2020.

Mr. Wang obtained his bachelor’s degree in polymer materials from Beijing Institute of Chemical Technology (北京化工學院) (now known as Beijing University of Chemical Technology (北京化工大學)) in the PRC in July 1986, his master of science degree in materials science and engineering from the University of Florida in the United States in December 1992 and his second master’s degree of business administration executive program from Temple University in the United States in May 2006.

### Non-executive Directors

**Mr. Peng Bo (彭博)**, aged 53, is a non-executive Director and chairman of our Board. Please refer to “—Board of Directors—Chairman of the Board” for his biography.

**Mr. Wang Lin (王琳)**, aged 48, was appointed as our Director on September 23, 2021 and was re-designated as our non-executive Director on December 16, 2021. He is primarily responsible for overseeing the management and operations of our Group.

From May 1997 to September 1998, Mr. Wang served as a project manager’s assistant and subcontract manager of Sinopec Engineering Incorporation (中國石化工程建設有限公司), a company principally engaged in engineering construction, where he was primarily responsible for project

---

## DIRECTORS AND SENIOR MANAGEMENT

---

management. From November 2003 to July 2005, Mr. Wang served as business development and marketing manager of Eli Lilly Asia Inc. (美國禮來亞洲公司), a company principally engaged in development and sales of pharmaceutical products, where he was primarily responsible for business development and marketing affairs. From August 2005 to February 2009, Mr. Wang served as a project manager of McKinsey & Company, a company principally engaged in management consulting services, where he was primarily responsible for project management. From February 2009 to February 2011, Mr. Wang served as a vice president of Zhejiang Hisun Pharmaceutical Co., Ltd. (浙江海正藥業股份有限公司), a pharmaceutical company whose shares are listed on the Shanghai Stock Exchange (stock code: 600267), where he was primarily responsible for business development and sales. From April 2011 to October 2013, Mr. Wang served as the strategic investment development director of China Resources Pharmaceutical Holdings Company Limited (華潤醫藥控股有限公司), a subsidiary of China Resources Pharmaceutical Group Limited (華潤醫藥集團有限公司), a pharmaceutical company whose shares are listed on the Stock Exchange (stock code: 3320) and general manager of Huarun Pien Tze Huang Pharmaceutical Co., Ltd. (華潤片仔癯藥業有限公司) (now known as Fujian Pien Tze Huang Health Technology co., Ltd. (福建片仔癯健康科技有限公司), a pharmaceutical company, respectively, where he was primarily responsible for the overall management. From October 2013 to January 2015, Mr. Wang served as a partner of Trustbridge Partners (摯信資本), a company principally engaged in investment and management consulting services, where Mr. Wang was primarily responsible for healthcare practice. From January 2015 to March 2017, he served as the general manager of Beijing Rogrand E-Commerce Co., Ltd. (北京融貫電子商務有限公司), a company principally engaged in operating ecommerce platform for pharmaceutical products, where he was primarily responsible for its overall management. From March 2018 to April 2019, he served as the co-president of Shanghai Tianyi Investment (Group) Co., Ltd. (上海天億實業控股集團有限公司), a company principally engaged in investment and management of healthcare related companies, where he was primarily responsible for investment management. Since April 2019, he has been serving as a consultant to companies regarding strategy and investment matters.

Mr. Wang graduated from Tianjin University (天津大學) in the PRC with a bachelor’s degree in managerial engineering in July 1994. He received his master’s degree in business administration in the China Europe International Business School (中歐國際工商學院) in the PRC April 2003.

**Ms. Wu Xia (吳夏)**, aged 40, was appointed as our Director on November 19, 2021 and was re-designated as our non-executive Director on December 16, 2021. She is primarily responsible for overseeing the management and operations of our Group.

Ms. Wu has over 10 years of experience in research and private equity investment focusing on healthcare industry. Ms. Wu joined CICC Jia Cheng Investment Management Company Limited (中金佳成投資管理有限公司) in July 2008 and served as vice president from January 2012 to December 2014 and as executive director from January 2015 to August 2018. Ms. Wu transferred into CICC Capital Management Co., Ltd. (中金資本運營有限公司) (“**CICC Capital**”) in August 2018 as an executive director and has been serving as a managing director of CICC Capital since January 2019, where she is primarily responsible for the overall investment and management of CICC Kangrui I (Ningbo) Equity Investment Limited Partners (Limited Partnership) (中金康瑞壹期(寧波)股權投資基金合夥企業(有限合夥)). Ms. Wu has also been serving as a director of Genetron Holdings Limited, a company whose shares are listed on the NASDAQ under the trading symbol of “GTH”, since September 2017, and a non-executive director of MicroPort CardioFlow Medtech Corporation (微創心

---

## DIRECTORS AND SENIOR MANAGEMENT

---

通醫療科技有限公司), a medical device company whose shares are listed on the Stock Exchange (stock code: 2160). She was awarded “Outstanding Young PE Investor of the Year 2018” by China Renaissance (華興資本) in 2018.

Ms. Wu obtained her bachelor’s degree in finance from Peking University (北京大學) in the PRC in July 2003 and her master’s degree in economics and finance from the University of Warwick in the United Kingdom in January 2005.

### Independent non-executive Directors

**Dr. Xu Yi (胥義)**, aged 46, was appointed as our independent non-executive Director on [●], 2022.

Dr. Xu has over 16 years of experience in researching on cryopreservation of cells, tissues and organs. He successively served as a lecturer and an associate professor from July 2005 to June 2017, and has been serving as a professor since June 2017, at the University of Shanghai for Science and Technology (上海理工大學), where he is primarily responsible for conducting research on biological thermodynamics. Dr. Xu also served as a senior research scholar at the University of Minnesota in the United States from January 2013 to January 2014.

From April 2017 to April 2021, Dr. Xu served as a deputy head of Cryobiology Group of China Medicinal Biotechnology Association Tissue Biobank Branch (中國醫藥生物技術協會組織生物樣本庫分會低溫生物學組). He has been serving as a committee member of the Biological Resource Management and Utilization Branch of the Chinese Preventive Medicine Association (中華預防醫學會生物資源管理與利用研究分會) since May 2018 and a member of the Tenth Council of Chinese Association of Refrigeration (中國製冷學會第十屆理事會) since October 2020.

Dr. Xu was awarded the Third Prize for Technology Invention Award of Shanghai (上海市技術發明獎三等獎) in November 2006, the Second Prize of Science and Technology Progress Award of Chinese Association of Refrigeration (中國製冷學會科學技術進步獎二等獎) in January 2007, the Second Prize for China Machinery Industry Technology Award (中國機械工業科學技術獎二等獎) in December 2007, the Shanghai Youth Science and Technology “Qimingxing” Program (Type A) (上海市青年科技“啟明星”計劃 (A類) 資助) in September 2008 and the Third Prize for Technology Invention Award of Shanghai (上海市技術發明獎三等獎) in December 2013.

Dr. Xu graduated from the China University of Mining and Technology (中國礦業大學) in the PRC with a bachelor’s degree in thermal engineering in July 1999 and a master’s degree in fluid machinery and engineering in June 2002. He obtained his doctor’s degree in refrigeration and cryogenic engineering from University of Shanghai for Science and Technology (上海理工大學) in the PRC in August 2005.

**Dr. Zhang Haixiao (張海曉)**, aged 50, was appointed as our independent non-executive Director on [●], 2022.

Dr. Zhang has over 23 years of working experience in law firms and acquired extensive corporate governance experience by providing legal consulting services including but not limited to anti-corruption compliance consulting, internal compliance investigation, intellectual property and anti-unfair competition law consulting services to a number of multinational companies and listed

## DIRECTORS AND SENIOR MANAGEMENT

companies. From October 1998 to March 2000, she served as a legal assistant at the Shanghai Representative Office of Schulz Noack Bärwinkel Law Firm (舒諾貝律師事務所上海辦事處). From March 2000 to July 2003, she served as a practicing lawyer at the Shanghai Office of Beijing Junhe Law Firm (北京市君合律師事務所上海分所). From September 2004 to July 2006, she worked at Shanghai Bangxinyang Law Firm (上海邦信陽律師事務所). From July 2006 to March 2008, she served as a senior associate at the Shanghai Representative Office of Weil Gotshal & Manages LLP (威嘉國際律師事務所上海代表處), where she was primarily responsible for providing legal advice on mergers and acquisitions. From March 2008 to May 2009, she successively served as a senior legal consultant at the Shanghai Representative Office of WongPartnership LLP and a partner at Shanghai Yuanda Law Firm (上海元達律師事務所). From July 2009 to April 2019, she served as a partner at Beijing Zhonglun (Shanghai) Law Firm (北京市中倫(上海)律師事務所), where she was primarily responsible for providing legal advice on anti-corruption, compliance, intellectual property and dispute resolution related matters. Since April 2019, she has been serving as a partner at Beijing Anjie Law Firm (北京安傑律師事務所), where she was mainly responsible for providing legal advice on anti-corruption, compliance, intellectual property and dispute resolution related matters. From 2015 to 2019, she was continuously rated as the “Leading Individual in Compliance” by the international legal ranking institution Legal Band. She has also been serving as an expert member of the Arbitration and Anti-Corruption Working Group of the ICC Arbitration and ADR Committee of the International Chamber of Commerce since November 2019.

Dr. Zhang obtained her first bachelor’s degree in industrial management engineering from Tongji University (同濟大學) (formerly known as Shanghai Institute of Building Materials Industry (上海建築材料工業學院)) in the PRC in July 1993 and her second bachelor’s degree in international economic law from Fudan University (復旦大學) in the PRC in July 1995. She obtained her master’s degree in law from University of Pennsylvania in the United States in May 2002 and her doctor’s degree in law from Fudan University (復旦大學) in the PRC in June 2013.

**Mr. Siu Chi Hung** (蕭志雄), aged 51, was appointed as our independent non-executive Director on [●], 2022.

Mr. Siu has over 25 years of accounting experience and has extensive experience in serving listed companies and IPO clients and advising on financial reporting, corporate governance, compliance and other listing rules matters in numerous occasions when he was an audit partner of KPMG. He joined KPMG Hong Kong in August 1994 and became a partner in July 2008. He was the head of real estate of KPMG (China) and the head of capital markets development, Southern China of KPMG (China) before his resignation in June 2018. From September 2019 to September 2021, he served as an executive director of LVGEM (China) Real Estate Investment Company Limited (綠景(中國)地產投資有限公司), a real estate developer and commercial property operator whose shares are listed on the Stock Exchange (stock code: 0095), where he was primarily responsible for corporate investment, treasury and financing, investor relationship and compliance management. Mr. Siu is also currently serving as an independent non-executive director of Roiserv Lifestyle Services Co., Ltd. (榮萬家生活服務股份有限公司), a property management service provider whose shares are listed on the Stock Exchange (stock code: 2146), an independent non-executive director at China Gas Industry Investment Holdings Co. Ltd., an industrial gas supplier whose shares are listed on the Stock Exchange (stock code: 1940), an independent non-executive director at Dongjiang Environmental Company Limited (東江環保股份有限公司), a hazardous waste disposal services provider whose

## **DIRECTORS AND SENIOR MANAGEMENT**

---

shares are listed on the Stock Exchange (stock code: 0895) and an independent non-executive director of Central China Management Company Limited (中原建業有限公司), a project management company for property development projects whose shares are listed on the Stock Exchange (stock code: 9982). Mr. Siu acquired solid knowledge and expertise on corporate governance and compliance matters, during his tenure as independent non-executive director at these listed companies, by reviewing their various continuing connected transactions annually, scrutinizing and monitoring performance reporting, exercising his independent judgment and providing impartial and external opinion to protect the interests of shareholders as a whole.

Mr. Siu obtained his bachelor's degree in business administration from the Chinese University of Hong Kong in Hong Kong in December 1994. He is currently a member of the Hong Kong Institute of Certified Public Accountants, a member of the American Institute of Certified Public Accountants and a member of the Hong Kong Independent Non-Executive Director Association. He also obtained an independent director qualification certificate of listed company from the Shenzhen Stock Exchange in February 2021.

Save as disclosed above, none of our Directors have held any other directorships in listed companies during the three years immediately preceding the date of this document. There is no other information relating to the relationship of any of our Directors with other Directors and senior management officers that should be disclosed pursuant to Rule 13.51(2) or paragraph 41(3) of Appendix 1A of the Listing Rules.

Save as disclosed herein, to the best of the knowledge, information and belief of our Directors having made all reasonable inquiries, there was no other matter with respect to the appointment of our Directors that needed to be brought to the attention of our Shareholders and there was no information relating to our Directors that was required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules as of the Latest Practicable Date.

## DIRECTORS AND SENIOR MANAGEMENT

### SENIOR MANAGEMENT

Our executive Directors and other members of our senior management are responsible for the day-to-day operations and management of the business of our Group. The table below sets forth the key information of our senior management:

<u>Name</u>	<u>Age</u>	<u>Date of joining our Group</u>	<u>Existing position(s) in our Group</u>	<u>Roles and responsibilities</u>
Mr. Xie Zhiyong (謝志永)	45	April 1, 2012	Executive Director and president	Responsible for the overall management of our Group
Mr. Wang Yiqun Bruce (王亦群)	57	June 15, 2015	Executive Director and executive vice president	Responsible for the R&D and international business of our Group
Mr. Duan Lei (段磊)	40	October 1, 2014	Vice president of sales and promotion of neuro-interventional solutions	Responsible for overall management of sales and promotion of neuro-interventional solutions of our Group
Ms. Lu Huina (盧惠娜)	38	April 1, 2016	Senior director of quality, regulatory and clinical affairs	Responsible for quality, regulatory and clinical affairs of our Group
Ms. Wu Zaoli (吳造力)	38	December 7, 2012	Senior director of human resources and administration	Responsible for human resources, administration and legal affairs of our Group
Mr. Xu Weili (徐偉力)	43	December 1, 2020	Senior director of promotion in South China	Responsible for product promotion in South China and providing strategic advice
Ms. Hou Zhuoping (後卓萍)	44	June 1, 2018	Advanced director of finance	Responsible for finance of our Group

**Mr. Xie Zhiyong (謝志永)**, aged 45, our executive Director and president. See “—Board of Directors—Executive Directors—Mr. Xie Zhiyong” of this section for his biography.

**Mr. Wang Yiqun Bruce (王亦群)**, aged 57, our executive Director and executive vice president. See “—Board of Directors—Executive Directors—Mr. Wang Yiqun Bruce” of this section for his biography.

**Mr. Duan Lei (段磊)**, aged 40, joined our Group on October 1, 2014 and has been serving as a vice president of sales and promotion of neuro-interventional solutions since then. He is primarily responsible for overall management of sales and promotion of neuro-interventional solutions of our Group.

Mr. Duan has over 15 years of experience in marketing and sales of medical devices. Prior to joining our Group, from July 2006 to September 2014, Mr. Duan successively served as a sales representative and sales manager in North China at Shanghai MicroPort Medical, where he was primarily responsible for the sales of coronary stents in North China from July 2006 to March 2012 and the sales of *APOLLO* in North China from March 2012 to September 2014.



---

## DIRECTORS AND SENIOR MANAGEMENT

---

Mr. Duan graduated from Jiangnan University (江南大學) in the PRC with a major in finance via distance learning in July 2018.

**Ms. Lu Huina** (盧惠娜), aged 38, joined our Group on April 1, 2016 as a manager of strategy and project management. From January 2017 to November 2020, Ms. Lu successively served as a senior manager of project management and clinical affairs, director of project management and clinical affairs and advanced director of R&D and clinical affairs. Since November 2020, Ms. Lu has been serving as a senior director of quality, regulatory and clinical affairs, primarily responsible for quality, regulatory and clinical affairs of our Group.

Prior to joining our Group, from March 2010 to March 2013, Ms. Lu served as a R&D engineer at Shanghai MicroPort Medical, where she was primarily responsible for R&D of neurovascular products. From April 2013 to March 2016, Ms. Lu served as a supervisor of product development of Shanghai MicroPort Medical, where she was primarily responsible for its product development. Ms. Lu received a Project Management Professional certificate from Project Management Institute in September 2012. She was awarded the Second Prize for Science and Technology Award of Shanghai Pudong New Area (上海市浦東新區科技進步二等獎) by the People’s Government of Shanghai Pudong New Area in January 2017 and Science and Technology Award of Shanghai (上海市科技進步獎) by the Shanghai Municipal People’s Government in December 2020.

Ms. Lu obtained her bachelor’s degree in polymer materials and engineering from Nanchang University (南昌大學) in the PRC in July 2007 and her master’s degree in material science from Shanghai University (上海大學) in the PRC in April 2010.

**Ms. Wu Zaoli** (吳造力), aged 38, joined our Group on December 7, 2012 as a manager of human resources and administration. From December 2012 to November 2020, Ms. Wu successively served as a manager, senior manager, director and advanced director of human resources and administration. Since November 2020, She has been serving as a senior director of human resources and administration, primarily responsible for human resources, administration and legal affairs of our Group.

Prior to joining our Group, from September 2007 to December 2012, Ms. Wu successively served as a human resources promotion specialist, head of editorial department and corporate culture manager at Shanghai MicroPort Medical, where she was primarily responsible for corporate culture affairs.

Ms. Wu obtained her bachelor’s degree in administrative management and master’s degree in industrial economics from Shanghai Maritime University (上海海事大學) in the PRC in July 2005 and October 2007, respectively.

**Mr. Xu Weili** (徐偉力), aged 43, joined our Group on December 1, 2020 and has been serving as a senior director of promotion in South China since then. He is primarily responsible for product promotion in South China and providing strategic advice.

Mr. Xu has over 20 years of experience in marketing and sales of pharmaceuticals and medical devices. Prior to joining our Group, from July 2001 to December 2002, Mr. Xu served as a marketing specialist at the marketing department of Shanghai Medical Institute (上海醫工院醫藥經銷部) where he was primarily responsible for marketing and promotion of pharmaceuticals. From January 2003 to

---

## DIRECTORS AND SENIOR MANAGEMENT

---

April 2006, Mr. Xu served as a professional medical representative at Xi'an Janssen Pharmaceutical Co., Ltd. (西安楊森製藥有限公司), a pharmaceutical company, where he was primarily responsible for promotion and sales of pharmaceuticals. From April 2006 to July 2007, Mr. Xu served as a senior sales representative at Bristol-Myers Squibb (Shanghai) Trading Company (百時美施貴寶(上海)貿易有限公司), a pharmaceutical products distributor, where he was primarily responsible for promotion and sales of tumor treatment pharmaceuticals. From July 2007 to July 2010, Mr. Xu served as a sales representative at Boston Scientific International Medical Trading (Shanghai) Co., Ltd. (波科國際醫療貿易(上海)有限公司) (“**Boston Scientific**”), a medical device company, where he was primarily responsible for promotion and sales of digestive intervention products in Shanghai. From July 2010 to April 2011, Mr. Xu served as a deputy product manager at Shanghai Roche Pharmaceutical Co., Ltd. (上海羅氏製藥有限公司), a pharmaceutical company. From July 2011 to September 2018, Mr. Xu successively served as a product manager and senior product manager at Stryker (Beijing) Medical Devices Co., Ltd. (史賽克(北京)醫療器械有限公司), a medical device manufacturer, where he was primarily responsible for promotion and sales of neurovascular interventional products. From September 2018 to November 2020, Mr. Xu served as a senior manager of national professional education and clinical training at Boston Scientific where he was primarily responsible for the national internal clinical training of the digestive intervention business department and the professional training of doctors. Mr. Xu was awarded the Stryker President's Club Award (史賽克總裁俱樂部獎) by Stryker Neurovascular in 2012.

Mr. Xu obtained his bachelor's degree in pharmaceutical enterprise management from China Pharmaceutical University (中國藥科大學) in the PRC in July 2001.

**Ms. Hou Zhuoping (後卓萍)**, aged 44, joined our Group on June 1, 2018 as a senior manager of finance. Since November 2020, she has been serving as an advanced director of finance, primarily responsible for finance of our Group.

Ms. Hou has over 22 years of experience in accounting and financial management. Prior to joining our Group, from June 1999 to April 2004, Ms. Hou successively worked at the Shanghai branch of Boli Food Industry (Kunshan) Co., Ltd. (波力食品工業(昆山)有限公司) (“**Boli Food**”), a food products manufacturer and distributor, Bote Plastics Industry (Shanghai) Co., Ltd. (波特塑料工業(上海)有限公司) and Boli Food. From July 2004 to March 2015, Ms. Hou successively served as an accountant and finance manager at Shanghai MicroPort Medical, where she was primarily responsible for its finance work. From March 2015 to May 2018, Ms. Hou served as a financial manager at MicroPort Endovascular where she was primarily responsible for its financial matters.

Ms. Hou obtained her bachelor's degree in accountancy from Fudan University (復旦大學) in the PRC in May 2008. Ms. Hou was certified as an Intermediate Accountant (中級會計師) by Shanghai Municipal Human Resources and Social Security Bureau (上海市人力資源和社會保障局) in July 2010. She was qualified as a board secretary by the Shanghai Stock Exchange (上海證券交易所董事會秘書) in July 2020.

### COMPANY SECRETARY

**Ms. Hui Yin Shan (許燕珊)**, aged 53, was appointed as our company secretary on December 16, 2021.

---

## DIRECTORS AND SENIOR MANAGEMENT

---

Ms. Hui is a senior manager of corporate services of Tricor Services Limited, a global professional services provider specializing in integrated business corporate and investor services. She has over 18 years of experience in the corporate secretarial field. Since October 2020, Ms. Hui has been the company secretary of OneForce Holdings Limited (元力控股有限公司), an investment holding company whose shares are listed on the Stock Exchange (stock code: 1933), the joint company secretary of Honliv Healthcare Management Group Company Limited (宏力醫療管理集團有限公司), a company operating private hospitals in the PRC whose shares are listed on the Stock Exchange (stock code: 9906) and the company secretary of Shanghai MicroPort MedBot (Group) Co., Ltd. (上海微創醫療機器人(集團)股份有限公司), a surgical robot company whose shares are listed on the Stock Exchange (stock code: 2252).

Ms. Hui graduated from Hong Kong Polytechnic University in Hong Kong with a bachelor’s degree in applied mathematics in November 1994. She received her master’s degree in finance from Curtin University of Technology in Australia in December 2002. Ms. Hui obtained a bachelor’s degree in law from University of London in the United Kingdom in August 2017. She is an associate member of the Hong Kong Chartered Governance Institute and the Chartered Governance Institute UK & Ireland, respectively.

### BOARD COMMITTEES

Our Board [has established] the audit committee, the remuneration committee and the nomination committee and delegated various responsibilities to these committees, which assist our Board in discharging its duties and overseeing particular aspects of our Group’s activities.

#### Audit Committee

We [have established] an audit committee with written terms of reference in compliance with Rule 3.21 of the Listing Rules and paragraphs C.3 of the Corporate Governance Code (“CG Code”) as set out in Appendix 14 to the Listing Rules. The audit committee consists of Mr. Siu Chi Hung, Dr. Xu Yi and Dr. Zhang Haixiao. Mr. Siu Chi Hung is the chairperson of the audit committee.

The primary duties of the audit committee are to (i) review and supervise our financial reporting process and internal control system of our Group, risk management and internal audit; (ii) provide advice and comments to our Board in respect of financial, risk management and internal control matters; and (iii) perform other duties and responsibilities as may be assigned by the Board.

#### Remuneration Committee

We [have established] a remuneration committee with written terms of reference in compliance with Rule 3.25 of the Listing Rules and paragraph B.1 of the CG Code as set out in Appendix 14 to the Listing Rules. The remuneration committee consists of Dr. Xu Yi, Mr. Peng Bo and Mr. Siu Chi Hung. Dr. Xu Yi is the chairperson of the remuneration committee.

The primary duties of the remuneration committee include, but not limited to (i) establishing, reviewing and providing advices to our Board on our policy and structure concerning remuneration of our Directors and senior management and on the establishment of a formal and transparent procedure for developing policies concerning such remuneration; (ii) determining the terms of the specific remuneration package of each Director and senior management; and (iii) reviewing and approving

## DIRECTORS AND SENIOR MANAGEMENT

---

performance-based remuneration by reference to corporate goals and objectives resolved by our Directors from time to time.

### Nomination Committee

We [have established] a nomination committee with written terms of reference in compliance with paragraph A.5 of the CG Code as set out in Appendix 14 to the Listing Rules. The nomination committee consists of Dr. Zhang Haixiao, Mr. Xie Zhiyong and Dr. Xu Yi. Dr. Zhang Haixiao is the chairperson of the nomination committee.

The primary duties of the nomination committee are to (i) review the structure, size and composition of our Board on a regular basis and make recommendations to the Board regarding any proposed changes to the composition of our Board; (ii) identify, select or make recommendations to our Board on the selection of individuals nominated for directorship, and ensure the diversity of our Board members; (iii) perform review on the contributions made by our Directors (including our independent non-executive Directors) and the sufficiency of time devoted to perform their duties; (iv) assess the independence of our independent non-executive Directors; and (v) make recommendations to our Board on relevant matters relating to the appointment, re-appointment and removal of our Directors and succession planning for our Directors.

### BOARD DIVERSITY POLICY

Our Board [has adopted] a board diversity policy which sets out the approach to achieve diversity on our Board. Our Company recognizes and embraces the benefits of having a diverse Board and sees increasing diversity at the Board level as an essential element in supporting the attainment of our Company’s strategic objectives and sustainable development. Our Company seeks to achieve Board diversity through the consideration of a number of factors, including but not limited to talent, skills, gender, age, cultural and educational background, ethnicity, professional experience, independence, knowledge and length of service. We will select potential Board candidates based on merit and his/her potential contribution to our Board while taking into consideration our own business model and specific needs from time to time. All Board appointments will be based on meritocracy and candidates will be considered against objective criteria, having due regard to the benefits of diversity on our Board.

Our Board has a balanced mix of knowledge, skills and experience, including but without limitation to medical device and engineering, electronics, private equity investment, biomedical engineering research, law and accounting. Members of our Board have obtained degrees in various majors including computer science, business administration, communications engineering, project management, finance, materials science refrigeration and cryogenic engineering, industrial management engineering and law. We have three independent non-executive Directors from different industry backgrounds, including biomedical engineering research, legal practice and accounting experience. Furthermore, our Directors are of a wide range of age, from 40 years old to 56 years old.

With regards to gender diversity on the Board, we recognize the particular importance of gender diversity. Our Board currently comprises two female Directors and six male Directors. We have taken and will continue to take steps to promote and enhance gender diversity at all levels of our Company, including but without limitation at our Board and senior management levels. Our board diversity

## DIRECTORS AND SENIOR MANAGEMENT

---

policy provides that our Board should aim to increase the proportion of female members over time after [REDACTED] where possible when selecting and making recommendations on suitable candidates for Board appointments. We will also ensure that there is gender diversity when recruiting staff at mid to senior level so that we will have a pipeline of female senior management and potential successors to our Board going forward. It is our objective to maintain an appropriate balance of gender diversity with reference to the expectations of stakeholders and international and local recommended best practices.

Our nomination committee is responsible for ensuring the diversity of our Board members. After [REDACTED], our nomination committee will review our board diversity policy and its implementation from time to time to monitor its continued effectiveness and we will disclose the implementation of our board diversity policy, including any measurable objectives set for implementing the board diversity policy and the progress on achieving these objectives, in our corporate governance report on an annual basis.

### COMPLIANCE ADVISOR

We have appointed Somerley Capital Limited as our compliance advisor pursuant to Rule 3A.19 of the Listing Rules. Pursuant to Rule 3A.23 of the Listing Rules, our compliance advisor will advise our Company in the following circumstances:

- before the publication of any regulatory announcement, circular and financial report;
- where a transaction, which might be notifiable or connected transaction, is contemplated including shares issues and share repurchases;
- where our Company proposes to use the [REDACTED] from the [REDACTED] in a manner different from that detailed in this document or where our business activities, developments or results deviate from any forecast, estimate or other information in this document; and
- where the Stock Exchange makes an inquiry of our Company regarding unusual movements in the [REDACTED] or [REDACTED] volume of our Shares.

The term of the appointment shall commence on the [REDACTED] and end on the date on which our Company distribute our annual report in respect of our financial results for the first full financial year commencing after the [REDACTED].

### COMPENSATION OF DIRECTORS AND SENIOR MANAGEMENT

Our Directors and members of our senior management receive compensation from our Group in the form of fees, salaries, allowances and benefits in kind, discretionary bonuses, retirement scheme contributions and equity-settled share-based payment.

The aggregate remuneration (including fees, salaries, allowances and benefits in kind, discretionary bonuses, retirement scheme contributions and equity-settled share-based payment) paid to our Directors for each of the three years ended December 31, 2021 was approximately RMB4.3 million, RMB4.6 million and RMB6.5 million, respectively. Save as disclosed above, no other amounts have been paid or are payable by any member of our Group to our Directors for each of the three years ended December 31, 2021.

---

## DIRECTORS AND SENIOR MANAGEMENT

---

The aggregate amount of salaries, other benefits, discretionary bonuses and equity-settled share-based payment paid to our five highest paid individuals in respect of each of the three years ended December 31, 2021 was approximately RMB8.1 million, RMB7.9 million and RMB12.7 million, respectively.

No remuneration was paid by us to our Directors or the five highest paid individuals as an inducement to join or upon joining us or as a compensation for loss of office in respect of each of the three years ended December 31, 2021. Further, none of our Directors had waived or agreed to waive any remuneration during the same periods.

Under the arrangement currently in force, the aggregate remuneration (including fees, salaries, allowances and benefits in kind, discretionary bonuses, retirement scheme contributions and equity-settled share-based payment) of our Directors for the year ending December 31, 2022 is estimated to be no more than approximately RMB5.3 million (excluding discretionary bonus).

Our Board will review and determine the remuneration and compensation packages of our Directors and senior management and will, following the [REDACTED], receive recommendation from the remuneration committee which will take into account salaries paid by comparable companies, time commitment and responsibilities of our Directors and performance of our Group.

### COMPETITION

Each of our Directors confirms that as of the Latest Practicable Date, he/she did not have any interest in a business, apart from the business of our Group, which competes or is likely to compete, either directly or indirectly, with our business, which would require disclosure under Rule 8.10 of the Listing Rules.

From time to time our non-executive Directors may serve on the boards of both private and public companies within the broader healthcare and medical device industries. However, as these non-executive Directors are neither our Controlling Shareholders nor members of our executive management team, we believe that their interests in such companies as directors would not render us incapable of carrying on our business independently from the other companies in which they may hold directorships from time to time.

### KEY TERMS OF EMPLOYMENT CONTRACTS

We normally enter into employment contracts, confidentiality agreements and non-competition agreements with our senior management members and other key personnel. Below sets forth the key terms of these contracts we have entered into with our senior management and other key personnel.

#### Confidentiality

- Scope of confidential information. Information that the employee shall keep confidential includes but is not limited to trade secrets, inventions, discoveries, technical updates and improvements, data (including but not limited to clinical data), design, know-how, market and sales conditions, information of distributors, customers and employee compensation of our Group and the MicroPort Group.
- Confidential obligation. The employee shall keep confidential information in confidence and shall not use, divulge, publish or otherwise disclose or allow to be disclosed any aspect

## DIRECTORS AND SENIOR MANAGEMENT

---

of confidential information to any entity or person whatsoever without the written consent of our Group.

- Confidential period. The confidentiality obligation shall continue to be in effect after the departure of the employee.

### **Non-competition**

Within one or two years from the date of the employee’s departure (the “**Non-compete Period**”), the employee shall not be engaged in any work, consulting or other services of any kind for any other person or business entity that competes with our Group. Our Group shall pay monthly compensation to the relevant employee during the Non-compete Period.

### **Service Invention**

The rights and interests in any invention, discovery, utility model, design and technical solution that produced by the employee within one year from the date of the employee’s departure during their employment, including but not limited to those (i) related to the employee’s work or (ii) developed in whole or in part using our equipment or confidential information, shall belong to us.

### **Non-solicitation**

The employee agrees that he/she shall not directly or indirectly, (i) solicit, induce, recruit or encourage any of our employees to leave our Group; and (ii) solicit our clients, within one or two years after termination of employment with our Group.

## **CORPORATE GOVERNANCE**

Our Company aims to achieve high standards of corporate governance which are crucial to the development and safeguard the interests of our Shareholders. To accomplish this, our Company expects to comply with the CG Code and the associated Listing Rules after the [REDACTED].